Halozyme Therapeutics reported $33M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 123.66M 2.71M Jun/2025
Agios Pharmaceuticals USD 45.87M 4.34M Jun/2025
Alnylam Pharmaceuticals USD 323.31M 83.36M Jun/2025
Amarin USD 36.57M 397K Mar/2025
Amgen USD 1.69B 4M Jun/2025
Baxter International USD 718M 15M Jun/2025
Cytokinetics USD 65.72M 8.35M Jun/2025
DBV Technologies USD 6.81M 2.5M Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Halozyme Therapeutics USD 33M 9.36M Jun/2025
Ionis Pharmaceuticals USD 90.6M 14.6M Jun/2025
MannKind USD 31.62M 6.61M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
United Therapeutics USD 212.5M 42.4M Jun/2025